[HTML][HTML] Mechanisms of transcriptional activation of the mouse claudin-5 promoter by estrogen receptor alpha and beta

M Burek, K Steinberg, CY Förster - Molecular and cellular endocrinology, 2014 - Elsevier
M Burek, K Steinberg, CY Förster
Molecular and cellular endocrinology, 2014Elsevier
Claudin-5 is an integral membrane protein and a critical component of endothelial tight
junctions that control paracellular permeability. Claudin-5 is expressed at high levels in the
brain vascular endothelium. Estrogens have multiple effects on vascular physiology and
function. The biological actions of estrogens are mediated by two different estrogen receptor
(ER) subtypes, ER alpha and ER beta. Estrogens have beneficial effects in several vascular
disorders. Recently we have cloned and characterized a murine claudin-5 promoter and …
Abstract
Claudin-5 is an integral membrane protein and a critical component of endothelial tight junctions that control paracellular permeability. Claudin-5 is expressed at high levels in the brain vascular endothelium. Estrogens have multiple effects on vascular physiology and function. The biological actions of estrogens are mediated by two different estrogen receptor (ER) subtypes, ER alpha and ER beta. Estrogens have beneficial effects in several vascular disorders. Recently we have cloned and characterized a murine claudin-5 promoter and demonstrated 17beta-estradiol (E2)-mediated regulation of claudin-5 in brain and heart microvascular endothelium on promoter, mRNA and protein level. Sequence analysis revealed a putative estrogen response element (ERE) and a putative Sp1 transcription factor binding site in the claudin-5 promoter. The aim of the present study was to further characterize the estrogen-responsive elements of claudin-5 promoter. First, we introduced point mutations in ERE or Sp1 site in −500/+111 or in Sp1 site of −268/+111 claudin-5 promoter construct, respectively. Basal and E2-mediated transcriptional activation of mutated constructs was abrogated in the luciferase reporter gene assay. Next, we examined whether estrogen receptor subtypes bind to the claudin-5 promoter region. For this purpose we performed chromatin immunoprecipitation assays using anti-estrogen receptor antibodies and cellular lysates of E2-treated endothelial cells followed by quantitative PCR analysis. We show enrichment of claudin-5 promoter fragments containing the ERE- and Sp1-binding site in immunoprecipitates after E2 treatment. Finally, in a gel mobility shift assay, we demonstrated DNA–protein interaction of both ER subtypes at ERE. In summary, this study provides evidence that both a non-consensus ERE and a Sp1 site in the claudin-5 promoter are functional and necessary for the basal and E2-mediated activation of the promoter.
Elsevier